Literature DB >> 1330172

Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade.

L J van Woerkens1, F Boomsma, A J Man in 't Veld, M M Bevers, P D Verdouw.   

Abstract

1. The effects of epinine or dopamine (both 1-10 micrograms kg-1 min-1) on systemic haemodynamics and plasma concentrations of catecholamines and prolactin were studied in conscious pigs before and after combined non-selective alpha- and beta-adrenoceptor blockade. 2. The plasma concentrations of the two compounds did not differ from each other over the entire dose-range. 3. Epinine increased aortic blood flow (AoBF, 24 +/- 6%), which was due to an increase in heart rate (HR) for doses less than 10 micrograms kg-1 min-1. At 10 micrograms kg-1 min-1, HR decreased slightly (10 +/- 3%, as compared to the value obtained at 5 micrograms kg-1 min-1) and stroke volume increased up to 15% (P < 0.05). Mean arterial pressure (MAP, 99 +/- 3 mmHg at baseline) decreased dose-dependently (14 +/- 2%, P < 0.05) up to the infusion rate of 5 micrograms kg-1 min-1, but increased by 4.0 +/- 1.8 mmHg during infusion of 10 micrograms kg-1 min-1. Systemic vascular resistance (SVR) decreased up to 23 +/- 3% for doses less than 10 micrograms kg-1 min-1, but did not change further during infusion of the highest dose. LVdP/dtmax increased during the two highest infusion rates up to 22 +/- 6% (P < 0.05). After the infusion was stopped there was an abrupt increase in HR (18 +/- 4%, P < 0.05) and a further decrease in SVR before all parameters returned to baseline.4. Dopamine caused increases in AoBF (27 +/- 3%) similar to epinine, the only difference being that HR continued to increase (32 +/- 5%) and MAP (13 +/- 3%) and SVR continued to decrease (31 +/- 3%) over the entire dose-range. The increase in LVdP/dt,,,, at the highest dose (48 +/- 4%, P <0.05) was more pronounced than with epinine.5. Adrenoceptor blockade inhibited all epinine-induced changes, but did not affect the dopamineinduced changes in AoBF, SVR and MAP, but attenuated the increases in HR and LVdP/dtmax.6. Noradrenaline (NA) and adrenaline (Ad) concentrations did not change during infusion of epinine or dopamine, but NA increased by 50% within 2.5 min after stopping the infusion of epinine. After adrenoceptor blockade NA and Ad concentrations did not change during infusion of dopamine, which contrasted with a decrease of 55 +/- 5% (P<0.05) in NA during infusion of epinine.7. Prolactin concentrations decreased gradually from 480 +/- 40 pg ml-' to 270 +/- 50 pg ml1' (P<0.05) during infusion of epinine, but did not change significantly during dopamine infusion.8. The differential effects of epinine and dopamine on MAP, SVR, plasma NA (before and after adrenoceptor blockade) and prolactin, leads us to conclude that in conscious pigs, epinine is a more potent a, P2 and D2-receptor agonist, but a weaker D,-receptor agonist than dopamine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330172      PMCID: PMC1907851          DOI: 10.1111/j.1476-5381.1992.tb12742.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection.

Authors:  F A van der Hoorn; F Boomsma; A J Man in 't Veld; M A Schalekamp
Journal:  J Chromatogr       Date:  1989-01-27

2.  Central catecholamine neuron systems: anatomy and physiology of the dopamine systems.

Authors:  R Y Moore; F E Bloom
Journal:  Annu Rev Neurosci       Date:  1978       Impact factor: 12.449

3.  Evaluation of the alpha and beta adrenoceptor-mediated activities of the novel, orally active inotropic agent, ibopamine, in the cardiovascular system of the pithed rat: comparison with epinine and dopamine.

Authors:  A J Nichols; R R Ruffolo
Journal:  J Pharmacol Exp Ther       Date:  1987-08       Impact factor: 4.030

Review 4.  Ibopamine in the treatment of heart failure.

Authors:  A J Man in't Veld
Journal:  Am J Med       Date:  1991-05-29       Impact factor: 4.965

5.  Simultaneous determination of free catecholamines and epinine and estimation of total epinine and dopamine in plasma and urine by high-performance liquid chromatography with fluorimetric detection.

Authors:  F Boomsma; G Alberts; F A van der Hoorn; A J Man in 't Veld; M A Schalekamp
Journal:  J Chromatogr       Date:  1992-02-07

6.  5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor.

Authors:  A H Bom; D J Duncker; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

7.  Effects of ibopamine on exercise-induced increase in norepinephrine in normal men.

Authors:  A R Girbes; D J Van Veldhuisen; R G Grevink; A J Smith; W D Reitsma
Journal:  J Cardiovasc Pharmacol       Date:  1992-03       Impact factor: 3.105

8.  Effects of intravenous epinine administration on left ventricular systolic performance, coronary hemodynamics, and circulating catecholamines in patients with heart failure.

Authors:  M F Rousseau; J Raigoso; C van Eyll; H Van Mechelen; N R Musso; G Lotti; H Pouleur
Journal:  J Cardiovasc Pharmacol       Date:  1992-02       Impact factor: 3.105

9.  Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors:  S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

10.  Pharmacological characterization of epinine 3-O-sulphate and 4-O-sulphate.

Authors:  R Ferrini; L Merlo; G Miragoli
Journal:  Arch Int Pharmacodyn Ther       Date:  1987-09
View more
  1 in total

Review 1.  Pharmacotherapy of congestive heart failure. Currently used and experimental drugs.

Authors:  P A van Zwieten
Journal:  Pharm World Sci       Date:  1994-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.